Literature DB >> 26843711

Treating hepatitis C - what's new?

Alex J Thompson1, Jacinta A Holmes2.   

Abstract

Chronic hepatitis C infection causes cirrhosis, liver failure and hepatocellular carcinoma, and is the most common indication for liver transplantation. Hepatitis C is curable and complications can be prevented. Until recently, treatment regimens involved peginterferon alfa. Although effective, their widespread use is limited by treatment-related toxicity. A number of direct-acting drugs for hepatitis C, such as sofosbuvir, have recently been developed and target multiple steps in the viral life cycle. These drugs are used in combination in interferon-free regimens. Short courses are highly effective with minimal toxicity.

Entities:  

Keywords:  asunaprevir; daclatasvir; hepatitis C; peginterferon; protease inhibitors; ribavirin; sofosbuvir

Year:  2015        PMID: 26843711      PMCID: PMC4674032          DOI: 10.18773/austprescr.2015.068

Source DB:  PubMed          Journal:  Aust Prescr        ISSN: 0312-8008


  21 in total

1.  Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies.

Authors:  M P Manns; M W Fried; S Zeuzem; I M Jacobson; X Forns; F Poordad; M Peeters; M Fu; O Lenz; S Ouwerkerk-Mahadevan; W Jessner; J A Scott; R Kalmeijer; G De La Rosa; R Sinha; M Beumont-Mauviel
Journal:  J Viral Hepat       Date:  2014-11-03       Impact factor: 3.728

2.  EASL Recommendations on Treatment of Hepatitis C 2015.

Authors: 
Journal:  J Hepatol       Date:  2015-04-21       Impact factor: 25.083

3.  Boceprevir for previously treated chronic HCV genotype 1 infection.

Authors:  Bruce R Bacon; Stuart C Gordon; Eric Lawitz; Patrick Marcellin; John M Vierling; Stefan Zeuzem; Fred Poordad; Zachary D Goodman; Heather L Sings; Navdeep Boparai; Margaret Burroughs; Clifford A Brass; Janice K Albrecht; Rafael Esteban
Journal:  N Engl J Med       Date:  2011-03-31       Impact factor: 91.245

4.  Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

Authors:  Alexander J Thompson; Andrew J Muir; Mark S Sulkowski; Dongliang Ge; Jacques Fellay; Kevin V Shianna; Thomas Urban; Nezam H Afdhal; Ira M Jacobson; Rafael Esteban; Fred Poordad; Eric J Lawitz; Jonathan McCone; Mitchell L Shiffman; Greg W Galler; William M Lee; Robert Reindollar; John W King; Paul Y Kwo; Reem H Ghalib; Bradley Freilich; Lisa M Nyberg; Stefan Zeuzem; Thierry Poynard; David M Vock; Karen S Pieper; Keyur Patel; Hans L Tillmann; Stephanie Noviello; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; David B Goldstein; John G McHutchison
Journal:  Gastroenterology       Date:  2010-04-24       Impact factor: 22.682

5.  Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

Authors:  Stefan Zeuzem; Geoffrey M Dusheiko; Riina Salupere; Alessandra Mangia; Robert Flisiak; Robert H Hyland; Ari Illeperuma; Evguenia Svarovskaia; Diana M Brainard; William T Symonds; G Mani Subramanian; John G McHutchison; Ola Weiland; Hendrik W Reesink; Peter Ferenci; Christophe Hézode; Rafael Esteban
Journal:  N Engl J Med       Date:  2014-05-04       Impact factor: 91.245

Review 6.  Chronic hepatitis C virus infection: genotyping and its clinical role.

Authors:  D Scott Bowden; Mark D Berzsenyi
Journal:  Future Microbiol       Date:  2006-06       Impact factor: 3.165

7.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

8.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Authors:  Nezam Afdhal; Stefan Zeuzem; Paul Kwo; Mario Chojkier; Norman Gitlin; Massimo Puoti; Manuel Romero-Gomez; Jean-Pierre Zarski; Kosh Agarwal; Peter Buggisch; Graham R Foster; Norbert Bräu; Maria Buti; Ira M Jacobson; G Mani Subramanian; Xiao Ding; Hongmei Mo; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Alessandra Mangia; Patrick Marcellin
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

9.  Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Jordan J Feld; Kris V Kowdley; Eoin Coakley; Samuel Sigal; David R Nelson; Darrell Crawford; Ola Weiland; Humberto Aguilar; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

10.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

View more
  5 in total

Review 1.  Daclatasvir.

Authors: 
Journal:  Aust Prescr       Date:  2015-10-01

2.  Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for chronic hepatitis C.

Authors: 
Journal:  Aust Prescr       Date:  2016-05-20

Review 3.  Asunaprevir.

Authors: 
Journal:  Aust Prescr       Date:  2015-11-19

Review 4.  Elbasvir/grazoprevir.

Authors: 
Journal:  Aust Prescr       Date:  2017-02-01

5.  Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016.

Authors:  Georgina Ireland; Sema Mandal; Matthew Hickman; Mary Ramsay; Ross Harris; Ruth Simmons
Journal:  Euro Surveill       Date:  2019-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.